Deletion of TET2 in colon tumor cells reduces chemokine and PD‐L1 expression, as well as tumor lymphocyte infiltration, allowing tumors to evade antitumor immunity and resist anti‐PD‐L1 therapy [254]. This evidence concerns the gene CD274 and colonic neoplasm.